Rarebase, PBC

05/24/2023

Our Director of Software Engineering, Clayton Mellina, believes a patient-centered approach, coupled with breakthrough technologies in machine learning and high-throughput biology, will drive a revolution in human health.

Uncover the power of big data with Clayton in our latest blog post: https://www.rarebase.org/post/unleashing-the-power-of-ai-on-rare-disease-drug-discovery

When Rarebase Director of Software Engineering Clayton Mellina first met Co-founder Onno Faber, he had just started a new engineering job at Google. He saw an upcoming genomics and AI event happening in San Francisco — an open genome hackathon for a patient with a rare auditory tumor disorder call...

05/17/2023

Rarebase makes extensive use of automation in our high-throughput labs. We’ve implemented the Hamilton Vantage liquid handler to automate our drug screening library preparation process in 384-well plate format. Since implementing this system, we’ve seen substantial improvements in speed and accuracy in our drug screens for our rare disease research studies.

05/13/2023

May 13th is World MED13L Syndrome Day. Please join us in recognizing the incredible efforts of organizations like our partner Med13L Foundation that are dedicated to advancing patient advocacy and research collaboration.

Together, we can help to support those affected by this rare genetic disorder and drive continued efforts towards finding effective treatments.

04/28/2023

Rarebase has generated a premier drug screening dataset that maximizes efficiency in drug hunting for rare neurological diseases. Learn more about our breakthrough approach to meet the urgent needs of the rare disease patient community: https://www.rarebase.org/post/how-the-rarebase-function-product-engine-maximizes-efficiency-in-rare-disease-drug-discovery

03/24/2023

In our latest podcast, our Director of High Throughput Biology, Joe Bellucci, PhD, walks us through advances in high-throughput screening and next-generation sequencing that have enabled tailored and scalable approaches to rare disease research. Catch our full conversation here: https://spotifyanchor-web.app.link/e/4QnJYQo3nyb

03/20/2023

Rare neurodevelopmental disorders are a focus of our drug discovery research at Rarebase — encompassing 77% of our current portfolio.

For National Developmental Disabilities Awareness Month, join us and the wider rare disease patient community in championing the support and inclusion of individuals affected by developmental disabilities.

03/17/2023

March 19th is CACNA1A Awareness Day, recognizing the impact of CACNA1A-related diseases on the daily lives of patients and their loved ones.

Rarebase stands with the community and patient organizations like Miren's Marathon at the Rare Village Foundation. We look forward to our continued collaboration with patient communities to unlock new opportunities for the millions affected by rare genetic diseases.

03/13/2023

Our discovery research team has been gearing up for compound testing in our Preclinical Stage! We brought our workhorse wild-type stem cells out of the freezer and gave them a rapid thaw. These cells will be expanded and differentiated into neurons for concentration-response studies with the drug repurposing candidates identified by Function.

03/08/2023

We sat down with our Scientific Founder and Advisor, Elizabeth Iorns, PhD, to dive into the science and technology behind the Rarebase drug discovery strategy.

Read more here: https://www.rarebase.org/post/reimagining-rare-disease-research-the-science-technology-behind-rarebase

02/28/2023

At Rarebase, we are filling the void in rare disease drug discovery to meet the urgent unmet needs of the rare disease community. This , learn how our precision medicine platform is advancing the hunt for new therapies: https://www.rarebase.org/post/3-700-disease-causing-genes-our-plan-to-fill-the-void-in-rare-disease-drug-discovery

02/24/2023

At Rarebase, we are committed to making a difference in the lives of those affected by rare diseases and we look forward to supporting next week. Sign up for our newsletter to follow our journey: http://eepurl.com/hKNGWr